Argenx To Advance ARGX-119 To Registrational Trial For Congenital Myasthenic Syndromes
Neutral
0.0
(RTTNews) - argenx SE (ARGX) announced that it plans to advance ARGX-119—a first-in-class agonist antibody targeting muscle-specific kinase (MuSK)—to a registrational study in patients with congenital myasthenic syndromes, following topline data from its Phase 1b trial.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
